Fondation Lenval Nice
- Address
- lock Available on a paid plan
Neurology and Oncology
Research at Fondation Lenval Nice includes studies in nervous system diseases and neoplasms, focusing on serious childhood conditions such as diffuse midline glioma and metachromatic leukodystrophy. These trials are designed to assess whether new treatment approaches can better slow disease progression and improve outcomes for young patients.
- Testing new therapies for aggressive pediatric brain tumors
- Evaluating treatment effects in metachromatic leukodystrophy
- Measuring whether therapies can preserve motor and survival outcomes
The site’s work in these areas reflects a strong commitment to rare and complex pediatric diseases, with research aimed at improving care where options remain limited.
Urology and Congenital Disorders
Clinical trials in male urogenital diseases and congenital, hereditary, and neonatal diseases address conditions such as posterior urethral valves, spina bifida, and Hirschsprung’s disease. The research is centered on improving bladder function, bowel recovery, and overall quality of life in children with structural or developmental disorders.
- Assessing treatments to improve bladder control and urinary function
- Studying recovery after surgery for Hirschsprung’s disease
- Exploring better management for congenital urinary tract abnormalities
These studies combine practical clinical goals with a focus on long-term functional outcomes in pediatric patients.
Infectious Diseases and Bone Infections
The site also conducts research in bacterial infections and mycoses, including studies of Gram-negative infections and acute osteomyelitis in children. The main purpose is to improve treatment strategies, support safer care outside the hospital when appropriate, and better understand how therapies work in young patients.
- Evaluating antibiotic use in serious pediatric infections
- Comparing outpatient and hospital-based care for osteomyelitis
- Improving recovery and treatment effectiveness in acute infections
This area highlights the site’s involvement in practical, patient-centered research for common and severe infectious conditions.
Metabolic Health and Respiratory Support
Trials in nutritional and metabolic diseases and respiratory tract diseases at this site include work on obesity and neuroendocrine cells hyperplasia of infancy. The research aims to support weight maintenance in adolescents and to evaluate whether treatment can reduce the need for oxygen therapy in infants with respiratory-related disease.
- Studying weight maintenance strategies in adolescents with obesity
- Assessing treatment effects in neuroendocrine cells hyperplasia of infancy
- Measuring improvements in breathing support needs over time
These studies show a broad interest in both long-term metabolic care and specialized pediatric respiratory conditions.
Anesthesia and Pain Management
Research in analytical, diagnostic and therapeutic techniques and equipment includes anesthesia and analgesia, with trials focused on severe acute trauma-related pain in children. The goal is to compare pain relief options and identify approaches that may offer faster and more effective comfort in emergency settings.
- Comparing pain-relief strategies for pediatric trauma
- Evaluating how well different treatments control severe acute pain
- Supporting better emergency care for injured children
This work emphasizes rapid symptom control and improved treatment choices for children in urgent care situations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondation Lenval Nice
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE) | Dbv Technologies | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One | 1 | Unknown | 2014-10-01 | 2014-10-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.